Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jan 23, 2019
TickeronGET DAILY SIGNALS
Waters (WAT, $203.66) Outpaces Earnings and Net Sales Estimates for Q4

Waters (WAT, $203.66) Outpaces Earnings and Net Sales Estimates for Q4

Waters Corporation reported fourth-quarter 2018 non-GAAP earnings of $2.87 per share, edging past Zacks Consensus Estimate by 22 cents. The earnings are +14.3% higher compared to the same quarter a year ago.

Net sales of the Analytical laboratory instrument manufacturing company came in at $715.02 million, beating Zacks Consensus Estimate of $702.52 million. Net sales increased +4.1% year-over-year.

Major contributors to sales growth included the company’s TA product line, strong demand in Asia (especially in China), and solid performance in the pharmaceutical market.

For 2019, Waters expects its non-GAAP earnings to be in the range of $9.20-$9.45 per share. It projects net sales to grow between 4% and 6% on a constant currency basis.

Related Ticker: WAT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


WAT in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 27, 2026

WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.

Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.876). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.542). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 21.35B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 42%. CDNA experienced the highest price growth at 24%, while ADVB experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 34%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 43
SMR Rating: 78
Profit Risk Rating: 85
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
WAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis

Industry MedicalSpecialties

Industry
Medical Specialties
Address
34 Maple Street
Phone
+1 508 478-2000
Employees
7900
Web
https://www.waters.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.
Waters (WAT, $203.66) Outpaces Earnings and Net Sales Estimates for Q4